Mylan N.V. (MYL) Upgraded at Barclays PLC
Barclays PLC upgraded shares of Mylan N.V. (NASDAQ:MYL) from an equal weight rating to an overweight rating in a research report sent to investors on Monday, May 22nd, MarketBeat.com reports. They currently have $50.00 price target on the stock, up from their previous price target of $47.00.
Other equities research analysts have also issued reports about the company. Royal Bank of Canada set a $41.00 target price on Mylan N.V. and gave the stock a hold rating in a research report on Saturday, May 13th. Cowen and Company reaffirmed a market perform rating and issued a $43.00 target price (down from $55.00) on shares of Mylan N.V. in a research report on Sunday, May 21st. Guggenheim reaffirmed a neutral rating on shares of Mylan N.V. in a research report on Friday, March 3rd. Leerink Swann reaffirmed an outperform rating on shares of Mylan N.V. in a research report on Monday, March 20th. Finally, Mizuho reaffirmed a buy rating and issued a $47.00 target price on shares of Mylan N.V. in a research report on Tuesday, February 28th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $50.77.
Mylan N.V. (NASDAQ:MYL) traded down 0.70% during mid-day trading on Monday, reaching $36.72. 8,784,868 shares of the company’s stock traded hands. Mylan N.V. has a 52 week low of $33.60 and a 52 week high of $50.40. The stock has a market capitalization of $19.68 billion, a PE ratio of 36.68 and a beta of 1.23. The stock’s 50 day moving average is $38.54 and its 200-day moving average is $38.99.
Mylan N.V. (NASDAQ:MYL) last posted its quarterly earnings results on Wednesday, May 10th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.92 by $0.01. The business had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.81 billion. Mylan N.V. had a return on equity of 23.69% and a net margin of 4.59%. The business’s revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.76 EPS. On average, equities analysts anticipate that Mylan N.V. will post $5.19 EPS for the current year.
In related news, President Rajiv Malik sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the completion of the transaction, the president now owns 799,855 shares in the company, valued at approximately $31,994,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Laboratories Abbott sold 44,000,000 shares of Mylan N.V. stock in a transaction on Thursday, March 23rd. The shares were sold at an average price of $41.60, for a total value of $1,830,400,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 44,035,000 shares of company stock valued at $1,831,800,000 in the last 90 days. 0.69% of the stock is owned by corporate insiders.
Institutional investors have recently modified their holdings of the stock. Mangrove Partners acquired a new position in shares of Mylan N.V. during the third quarter valued at about $7,624,000. Hsbc Holdings PLC increased its position in shares of Mylan N.V. by 77.8% in the third quarter. Hsbc Holdings PLC now owns 21,102 shares of the company’s stock valued at $798,000 after buying an additional 9,232 shares during the last quarter. Zacks Investment Management increased its position in shares of Mylan N.V. by 2.5% in the third quarter. Zacks Investment Management now owns 160,300 shares of the company’s stock valued at $6,111,000 after buying an additional 3,969 shares during the last quarter. Commonwealth Bank of Australia increased its position in shares of Mylan N.V. by 6.8% in the third quarter. Commonwealth Bank of Australia now owns 29,727 shares of the company’s stock valued at $1,133,000 after buying an additional 1,900 shares during the last quarter. Finally, Zweig DiMenna Associates LLC acquired a new position in shares of Mylan N.V. during the third quarter valued at about $221,000. Hedge funds and other institutional investors own 69.95% of the company’s stock.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.